Curaleaf Holdings (CURLF) Other Operating Expenses (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Other Operating Expenses of $43.3 million for Q1 2026, up 1272.69% year-on-year from $3.2 million in Q1 2025, and down 8.74% on a QoQ basis from $47.5 million in Q4 2025.
Curaleaf Holdings (CURLF) Other Operating Expenses (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Other Operating Expenses for 8 consecutive years, with $43.3 million the latest figure, recorded in Q1 2026.
- Quarterly Other Operating Expenses rose 1272.69% year-over-year to $43.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $180.4 million (up 20.27% YoY) and the FY2025 annual result came in at $177.1 million, down 10.31% from the prior year.
- Other Operating Expenses eased to $43.3 million in Q1 2026 per CURLF's latest filing, from $47.5 million in the prior quarter.
- Over the last five years, Other Operating Expenses for CURLF reached as high as $142.1 billion in Q4 2023 and fell as low as -$144.5 million in Q4 2022.
- A 5-year average of $8.4 billion and a median of $43.3 million in 2026 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2022 — Other Operating Expenses slumped 6807.69% — and 2023, when it jumped 98484.02%.
- Year by year, Other Operating Expenses stood at -$144.5 million in 2022, then soared by 98484.02% to $142.1 billion in 2023, then tumbled by 99.95% to $65.3 million in 2024, then slipped by 27.27% to $47.5 million in 2025, then slipped by 8.74% to $43.3 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $43.3 million, $47.5 million, and $45.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.33 Mn |
| Dec 31, 2025 | 47.48 Mn |
| Sep 30, 2025 | 45.53 Mn |
| Jun 30, 2025 | 44.05 Mn |
| Mar 31, 2025 | -3.70 Mn |
| Dec 31, 2024 | 65.29 Mn |
| Sep 30, 2024 | 44.99 Mn |
| Jun 30, 2024 | 43.41 Mn |
| Mar 31, 2024 | 43.81 Mn |
| Dec 31, 2023 | 142.13 Bn |
| Sep 30, 2023 | -24.79 Mn |
| Jun 30, 2023 | 43.33 Mn |
| Mar 31, 2023 | 31.98 Mn |
| Dec 31, 2022 | -144.46 Mn |
| Sep 30, 2022 | 33.45 Mn |
| Jun 30, 2022 | 36.12 Mn |
| Mar 31, 2022 | -872,000.00 |
| Dec 31, 2021 | -8.90 Mn |
| Sep 30, 2021 | 1.32 Mn |
| Jun 30, 2021 | -753,000.00 |